NZ600305A - Mglu2 agonists - Google Patents

Mglu2 agonists

Info

Publication number
NZ600305A
NZ600305A NZ600305A NZ60030510A NZ600305A NZ 600305 A NZ600305 A NZ 600305A NZ 600305 A NZ600305 A NZ 600305A NZ 60030510 A NZ60030510 A NZ 60030510A NZ 600305 A NZ600305 A NZ 600305A
Authority
NZ
New Zealand
Prior art keywords
amino
triazol
bicyclo
hexane
ylsulfanyl
Prior art date
Application number
NZ600305A
Other languages
English (en)
Inventor
Bruce William Shaw
Martinez Lorena Taboada
Lourdes Prieto
James Allen Monn
Salgado Carlos Montero
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42026702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ600305(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NZ600305A publication Critical patent/NZ600305A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ600305A 2009-12-21 2010-12-15 Mglu2 agonists NZ600305A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09382290 2009-12-21
US30523910P 2010-02-17 2010-02-17
PCT/US2010/060371 WO2011084437A1 (en) 2009-12-21 2010-12-15 Mglu2 agonists

Publications (1)

Publication Number Publication Date
NZ600305A true NZ600305A (en) 2014-01-31

Family

ID=42026702

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ600305A NZ600305A (en) 2009-12-21 2010-12-15 Mglu2 agonists

Country Status (35)

Country Link
US (1) US8318184B2 (OSRAM)
EP (1) EP2516406B1 (OSRAM)
JP (1) JP5779190B2 (OSRAM)
KR (1) KR101395356B1 (OSRAM)
CN (1) CN102695701B (OSRAM)
AR (1) AR079343A1 (OSRAM)
AU (1) AU2010340039B2 (OSRAM)
BR (1) BR112012017188B1 (OSRAM)
CA (1) CA2784667C (OSRAM)
CR (1) CR20120322A (OSRAM)
CY (1) CY1114880T1 (OSRAM)
DK (1) DK2516406T3 (OSRAM)
DO (1) DOP2012000173A (OSRAM)
EA (1) EA020229B1 (OSRAM)
EC (1) ECSP12011989A (OSRAM)
ES (1) ES2435651T3 (OSRAM)
HN (1) HN2012001160A (OSRAM)
HR (1) HRP20131052T1 (OSRAM)
IL (1) IL220011A (OSRAM)
JO (1) JO2978B1 (OSRAM)
MA (1) MA33824B1 (OSRAM)
MX (1) MX2012007332A (OSRAM)
MY (1) MY160618A (OSRAM)
NZ (1) NZ600305A (OSRAM)
PE (1) PE20121688A1 (OSRAM)
PH (1) PH12012501253A1 (OSRAM)
PL (1) PL2516406T3 (OSRAM)
PT (1) PT2516406E (OSRAM)
RS (1) RS53063B (OSRAM)
SG (1) SG181836A1 (OSRAM)
SI (1) SI2516406T1 (OSRAM)
TN (1) TN2012000281A1 (OSRAM)
TW (1) TWI477490B (OSRAM)
UA (1) UA107684C2 (OSRAM)
WO (1) WO2011084437A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011216404B2 (en) 2010-02-17 2016-04-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
AR083845A1 (es) * 2010-11-18 2013-03-27 Lilly Co Eli COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3
JP5870111B2 (ja) * 2010-11-18 2016-02-24 イーライ リリー アンド カンパニー mGluR2/3アンタゴニストとしての4−置換−3−ベンジルオキシ−ビシクロ[3.1.0]ヘキサン化合物
HRP20160676T1 (hr) * 2011-06-17 2016-07-15 Eli Lilly And Company Derivati biciklo[3.1.0]heksan-2,6-dikarboksilne kiseline kao agonisti receptora mglu2
AR089718A1 (es) * 2012-02-01 2014-09-10 Lilly Co Eli AGONISTAS DE mGlu2/3
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
AU2015208233B2 (en) 2014-01-21 2019-08-29 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
MX374909B (es) 2015-04-01 2025-03-06 Akebia Therapeutics Inc El uso del inhibidor de propil hidrolasa del factor inducible de hipoxia (hif) para el tratamiento o prevención de la anemia.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576323A (en) * 1993-12-03 1996-11-19 Eli Lilly And Company Excitatory amino acid receptor antagonists
GB9605429D0 (en) * 1995-11-16 1996-05-15 Lilly Co Eli Excitatory amino acid receptor antagonists
US5688826A (en) 1995-11-16 1997-11-18 Eli Lilly And Company Excitatory amino acid derivatives
ZA983930B (en) 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
HUP0400620A3 (en) * 2001-01-11 2012-09-28 Lilly Co Eli Prodrugs of excitatory amino acids and pharmaceutical compositions containing them and process for preparation the compounds
EP1351925A1 (en) * 2001-01-11 2003-10-15 Eli Lilly And Company Prodrugs of excitatory amino acids
EP1370519A1 (en) * 2001-02-22 2003-12-17 Eli Lilly And Company Synthetic excitatory amino acids
HRP20090058A2 (hr) 2002-06-11 2009-04-30 Eli Lilly And Company Prekursorski oblici lijekova za aminokiseline s pobuđivačkom aktivnosti
US7381746B2 (en) * 2003-06-26 2008-06-03 Taisho Pharmaceutical Co., Ltd. 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative
AR083845A1 (es) * 2010-11-18 2013-03-27 Lilly Co Eli COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3
JP5870111B2 (ja) * 2010-11-18 2016-02-24 イーライ リリー アンド カンパニー mGluR2/3アンタゴニストとしての4−置換−3−ベンジルオキシ−ビシクロ[3.1.0]ヘキサン化合物

Also Published As

Publication number Publication date
TWI477490B (zh) 2015-03-21
BR112012017188B1 (pt) 2021-06-22
CN102695701B (zh) 2014-10-01
EP2516406A1 (en) 2012-10-31
PH12012501253A1 (en) 2014-08-01
HN2012001160A (es) 2015-08-24
HRP20131052T1 (hr) 2013-12-06
ES2435651T3 (es) 2013-12-20
KR101395356B1 (ko) 2014-05-14
MA33824B1 (fr) 2012-12-03
TN2012000281A1 (en) 2013-12-12
CN102695701A (zh) 2012-09-26
AU2010340039B2 (en) 2014-03-20
JP2013514974A (ja) 2013-05-02
JO2978B1 (en) 2016-03-15
DOP2012000173A (es) 2012-11-30
DK2516406T3 (da) 2013-10-14
SG181836A1 (en) 2012-08-30
CA2784667C (en) 2014-11-18
EA020229B1 (ru) 2014-09-30
RS53063B (sr) 2014-04-30
PE20121688A1 (es) 2012-12-05
KR20120094056A (ko) 2012-08-23
TW201144290A (en) 2011-12-16
SI2516406T1 (sl) 2013-11-29
BR112012017188A8 (pt) 2016-10-04
CY1114880T1 (el) 2016-12-14
AU2010340039A1 (en) 2012-08-09
BR112012017188A2 (pt) 2016-03-22
US20110152334A1 (en) 2011-06-23
CR20120322A (es) 2012-07-10
JP5779190B2 (ja) 2015-09-16
WO2011084437A1 (en) 2011-07-14
EA201290558A1 (ru) 2012-12-28
ECSP12011989A (es) 2012-07-31
IL220011A0 (en) 2012-07-31
PT2516406E (pt) 2013-10-10
EP2516406B1 (en) 2013-09-18
AR079343A1 (es) 2012-01-18
MY160618A (en) 2017-03-15
HK1171228A1 (en) 2013-03-22
US8318184B2 (en) 2012-11-27
UA107684C2 (xx) 2015-02-10
PL2516406T3 (pl) 2014-03-31
CA2784667A1 (en) 2011-07-14
IL220011A (en) 2014-03-31
MX2012007332A (es) 2012-07-20

Similar Documents

Publication Publication Date Title
NZ600305A (en) Mglu2 agonists
GEP201706608B (en) 1 - arylcarbonyl - 4 - oxy – piperidine compounds useful for the treatment of neurodegenerative diseases
MX2008012404A (es) Derivados de amida y su aplicacion para el tratamiento de enfermedades relacionadas con proteina-g.
TN2009000199A1 (en) Heteromonocyclic compound and use thereof
GEP20146125B (en) Aminopyrimidines as syk inhibitors
GEP20156285B (en) Compounds and compositions as trk inhibitors
EA201400358A1 (ru) Замещенные n-[1-циано-2-(фенил)этил]-2-азабицикло[2.2.1]гептан-3-карбоксамидные ингибиторы катепсина с
PE20140966A1 (es) Quinazolincarboxamida azetidinas
MX2009012923A (es) Amidas del acido pirazol carboxilico utiles como microbiocidas.
BR112015012425A2 (pt) composto, composição farmacêutica, método e medicamento para o tratamento de doenças medicadas pela proteína parp-1 e uso do composto
GEP20166483B (en) Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament
PT2421879E (pt) Novos 7-deazapurina nucleósidos para utilizações terapêuticas
MA35434B1 (fr) Amino-quinazolines en tant qu'inhibiteurs de kinase
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
TNSN07383A1 (en) 1-h-quinazoline-2,4-diones and their use as ampa-receptor ligands
NI200900151A (es) Nuevo procedimiento de síntesis de la agomelatina.
WO2009067493A3 (en) 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders
TN2009000287A1 (en) Cyclized derivatives as eg-5inhibitors
CY1110943T1 (el) Νεα μεθοδος διαχωρισμου των εναντιομερων του (3,4-διμεθοξυδικυκλο[4.2.0]οκτα-1,3,5-τριεν-7-υλ) νιτριλιου και εφαρμογη στη συνθεση της ιβαβραδινης
MY166889A (en) Inhibitors of nedd8-activating enzyme
IL202236A0 (en) Prolinamide derivatives as nk3 antagonists
MY147188A (en) Substituted imidazole compounds as ksp inhibitors
GB201114389D0 (en) Novel compounds
BR112015021393A2 (pt) processo para a preparação de (2s,5r)-7-oxo-6-sulfoóxi-2-[(((3r)-piperidina-3-carbonil)-hidrazina carbonil]-1,6-diaza-biciclo[3.2.1]- octano
UA94615C2 (uk) Інгібітори транспортера-1 гліцину

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 15 DEC 2017 BY THOMSON REUTERS

Effective date: 20140912

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 DEC 2018 BY THOMSON REUTERS

Effective date: 20171120

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 DEC 2019 BY THOMSON REUTERS

Effective date: 20181116

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 DEC 2020 BY THOMSON REUTERS

Effective date: 20191116

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 DEC 2021 BY THOMSON REUTERS

Effective date: 20200926

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 DEC 2022 BY ANAQUA SERVICES

Effective date: 20211117

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 DEC 2023 BY ANAQUA SERVICES

Effective date: 20221124

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 DEC 2024 BY ANAQUA SERVICES

Effective date: 20231122

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 DEC 2025 BY ANAQUA SERVICES

Effective date: 20241122

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 DEC 2026 BY ANAQUA SERVICES

Effective date: 20251119